QVT Associates GP LLC
10% Owner
QVT Associates GP LLC10% Owner
QVT Associates GP LLC insider trades: Urovant Sciences (UROV) stock buys and sales
10% Owner, Urovant Sciences Last trade Jun 19, 2019 83 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
81
Open-market trades
since 2009
13
Companies
last trade 2019
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where QVT Associates GP LLC reports to the SEC
UROVUrovant Sciences
10% Owner · last filing Jun 19, 2019
+$38.7M
MYOVMyovant Sciences
10% Owner · last filing Jun 6, 2019
+$42.5M
AXONAxovant Sciences
10% Owner · last filing Mar 19, 2019
+$45.0M
ABUSArbutus Biopharma
Director · last filing Jan 16, 2018
No market trades
AGENAgenus
10% Owner · last filing Jan 13, 2015
-$12.5M
ACHNAchillion Pharmaceuticals
10% Owner · last filing Jun 18, 2014
-$27.5M
+$22.4M
and 7 more companies
Open-market buys and sales
81 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 19, 2019 | UROV | ↑ Buy10b5-1 | 18,204 | $8.32 | $151K | (see fn5) | Jun 19, 2019 (0d) |
| Jun 14, 2019 | UROV | ↑ Buy10b5-1 | 22,011 | $8.06 | $177K | (see fn5) | Jun 14, 2019 (0d) |
| Jun 11, 2019 | UROV | ↑ Buy10b5-1 | 21,338 | $8.31 | $177K | Indirect | Jun 11, 2019 (0d) |
| Jun 6, 2019 | UROV | ↑ Buy10b5-1 | 21,122 | $7.86 | $166K | Indirect | Jun 6, 2019 (0d) |
| Jun 4, 2019 | MYOV | ↑ Buy | 2,424,242 | $8.25 | $20.0M | see fn | Jun 6, 2019 (2d) |
| Jun 3, 2019 | UROV | ↑ Buy10b5-1 | 17,746 | $7.83 | $139K | Indirect | Jun 3, 2019 (0d) |
| May 29, 2019 | UROV | ↑ Buy10b5-1 | 14,485 | $7.63 | $110K | (see fn5) | May 29, 2019 (0d) |
| May 23, 2019 | UROV | ↑ Buy10b5-1 | 19,830 | $8.22 | $163K | (see fn6) | May 23, 2019 (0d) |
| May 20, 2019 | UROV | ↑ Buy | 21,608 | $7.54 | $163K | (see fn6) | May 20, 2019 (0d) |
| Mar 18, 2019 | AXON | ↑ Buy | 6,666,667 | $1.50 | $10.0M | see fn | Mar 19, 2019 (1d) |
| Dec 18, 2018 | AXON | ↑ Buy | 10,000,000 | $1.00 | $10.0M | see fn | Dec 20, 2018 (2d) |
| Oct 1, 2018 | UROV | ↑ Buy | 2,678,571 | $14.00 | $37.5M | see fn | Oct 3, 2018 (2d) |
| Jun 5, 2018 | AXON | ↑ Buy | 14,285,714 | $1.75 | $25.0M | see fn | Jun 7, 2018 (2d) |
| Apr 2, 2018 | MYOV | ↑ Buy | 1,110,015 | $20.27 | $22.5M | Indirect | Apr 4, 2018 (2d) |
| Jan 9, 2015 | AGEN | ↓ Sell | 2,343,630 | $5.31 | $12.5M | Through QVT Fund IV LP, QVT Fund V LP an | Jan 13, 2015 (4d) |
| Jun 16, 2014 | ACHN | ↓ Sell | 1,819,551 | $7.70 | $14.0M | Through QVT Fund IV LP, QVT Fund V LP an | Jun 18, 2014 (2d) |
| Jun 11, 2014 | ACHN | ↓ Sell | 128,649 | $7.66 | $986K | Through QVT Fund IV LP, QVT Fund V LP an | Jun 12, 2014 (1d) |
| Feb 19, 2014 | CNCE | ↑ Buy | 300,000 | $14.00 | $4.2M | Through QVT Fund IV LP, QVT Fund V LP an | Feb 21, 2014 (2d) |
| Dec 30, 2013 | ACHN | ↓ Sell | 170,239 | $3.34 | $569K | Through QVT Fund IV LP, QVT Fund V LP an | Dec 31, 2013 (1d) |
| Dec 26, 2013 | ACHN | ↓ Sell | 121,205 | $3.44 | $417K | Through QVT Fund IV LP, QVT Fund V LP an | Dec 27, 2013 (1d) |
| Dec 23, 2013 | ACHN | ↓ Sell | 289,141 | $3.24 | $938K | Through QVT Fund IV LP, QVT Fund V LP an | Dec 24, 2013 (1d) |
| Dec 19, 2013 | ACHN | ↓ Sell | 222,612 | $3.09 | $687K | Through QVT Fund IV LP, QVT Fund V LP an | Dec 20, 2013 (1d) |
| Dec 17, 2013 | ACHN | ↓ Sell | 92,803 | $3.11 | $288K | Through QVT Fund IV LP, QVT Fund V LP an | Dec 18, 2013 (1d) |
| Sep 30, 2013 | ACHN | ↓ Sell | 2,754,900 | $3.47 | $9.6M | Through QVT Fund IV LP, QVT Fund V LP an | Oct 2, 2013 (2d) |
| Aug 9, 2013 | ACHN | ↑ Buy | 102,282 | $6.41 | $656K | Through QVT Fund IV LP, QVT Fund V LP an | Aug 12, 2013 (3d) |
| Jul 11, 2013 | ACHN | ↑ Buy | 401,017 | $6.46 | $2.6M | Through QVT Fund IV LP, QVT Fund V LP an | Jul 15, 2013 (4d) |
| Jul 10, 2013 | ACHN | ↑ Buy | 390,944 | $6.33 | $2.5M | Through QVT Fund IV LP, QVT Fund V LP an | Jul 11, 2013 (1d) |
| Jul 8, 2013 | ACHN | ↑ Buy | 642,509 | $6.28 | $4.0M | Through QVT Fund IV LP, QVT Fund V LP an | Jul 9, 2013 (1d) |
| Jul 3, 2013 | ACHN | ↑ Buy | 1,963,248 | $6.43 | $12.6M | Through QVT Fund IV LP, QVT Fund V LP an | Jul 5, 2013 (2d) |
| Oct 21, 2011 | ANDS | ↓ Sell | 5,617,618 | $3.68 | $20.7M | Through QVT Fund LP and Quintessence Fun | Oct 24, 2011 (3d) |
| Oct 17, 2011 | ANDS | ↓ Sell | 650,100 | $3.68 | $2.4M | Through QVT Fund LP and Quintessence Fun | Oct 19, 2011 (2d) |
| Sep 27, 2011 | INHX | ↓ Sell | 233,900 | $3.00 | $701K | Through QVT Fund LP and Quintessence Fun | Sep 28, 2011 (1d) |
| Jun 7, 2011 | MDVN | ↓ Sell | 368,147 | $22.62 | $8.3M | Through QVT Fund LP and Quintessence Fun | Jun 9, 2011 (2d) |
| Jun 6, 2011 | MDVN | ↓ Sell | 268,755 | $22.49 | $6.0M | Through QVT Fund LP and Quintessence Fun | Jun 6, 2011 (0d) |
| May 31, 2011 | INHX | ↓ Sell | 655,000 | $4.50 | $2.9M | Through QVT Fund LP and Quintessence Fun | Jun 2, 2011 (2d) |
| Apr 11, 2011 | INHX | ↓ Sell | 604,191 | $4.39 | $2.7M | Through QVT Fund LP and Quintessence Fun | Apr 11, 2011 (0d) |
| Jan 3, 2011 | ANDS | ↑ Buy | 34,209 | $1.41 | $48K | Through QVT Fund LP and Quintessence Fun | Jan 5, 2011 (2d) |
| Dec 31, 2010 | TPCG | ↓ Sell | 14,000 | $30.77 | $431K | Through QVT Fund LP and Quintessence Fun | Jan 4, 2011 (4d) |
| Dec 30, 2010 | ANDS | ↑ Buy | 317,314 | $1.45 | $461K | Through QVT Fund LP and Quintessence Fun | Jan 3, 2011 (4d) |
| Dec 28, 2010 | ANDS | ↑ Buy | 2,258,900 | $1.33 | $3.0M | Through QVT Fund LP and Quintessence Fun | Dec 29, 2010 (1d) |
| Dec 28, 2010 | TPCG | ↓ Sell | 73,600 | $30.83 | $2.3M | Through QVT Fund LP and Quintessence Fun | Dec 29, 2010 (1d) |
| Dec 23, 2010 | ANDS | ↑ Buy | 285,790 | $1.21 | $346K | Through QVT Fund LP and Quintessence Fun | Dec 27, 2010 (4d) |
| Nov 29, 2010 | MDVN | ↑ Buy | 200 | $11.00 | $2K | Through QVT Fund LP and Quintessence Fun | Dec 1, 2010 (2d) |
| Nov 23, 2010 | MDVN | ↑ Buy | 2,100 | $10.99 | $23K | Through QVT Fund LP and Quintessence Fun | Nov 26, 2010 (3d) |
| Nov 17, 2010 | MDVN | ↑ Buy | 400 | $11.00 | $4K | Through QVT Fund LP and Quintessence Fun | Nov 19, 2010 (2d) |
| Oct 27, 2010 | MDVN | ↑ Buy | 55,815 | $11.43 | $638K | Through QVT Fund LP and Quintessence Fun | Oct 28, 2010 (1d) |
| Oct 25, 2010 | MDVN | ↑ Buy | 157,196 | $11.28 | $1.8M | Through QVT Fund LP and Quintessence Fun | Oct 26, 2010 (1d) |
| Oct 20, 2010 | ANDS | ↑ Buy | 150,000 | $1.65 | $248K | Through QVT Fund LP and Quintessence Fun | Oct 22, 2010 (2d) |
| Oct 15, 2010 | ANDS | ↑ Buy | 2,301,389 | $1.78 | $4.1M | Through QVT Fund LP and Quintessence Fun | Oct 19, 2010 (4d) |
| Sep 17, 2010 | MDVN | ↑ Buy | 29,650 | $11.49 | $341K | Through QVT Fund LP and Quintessence Fun | Sep 20, 2010 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About QVT Associates GP LLC's insider trades
QVT Associates GP LLC is a 10% owner of Urovant Sciences (UROV). Since Sep 24, 2009, it has reported 62 open-market purchases worth $170.4M and 19 sales worth $105.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include other transactions (2 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every UROV insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.